CVS Health (CVS) Stock Forecast & Price Target

$65.30 -0.62 (-0.94%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$65.45 +0.15 (+0.23%)

As of 04/25/2025 07:59 PM Eastern

CVS Health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 22 Analyst Ratings

Sell
0

Hold
3

Buy
19

Based on 22 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 3 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for CVS.

Consensus Price Target

$71.94
10.17% Upside

According to the 22 analysts' twelve-month price targets for CVS Health, the average price target is $71.94. The highest price target for CVS is $82.00, while the lowest price target for CVS is $58.00. The average price target represents a forecasted upside of 10.17% from the current price of $65.30.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

CVS Analyst Ratings Over Time

Type	Current Forecast 4/26/24 to 4/26/25	1 Month Ago 3/27/24 to 3/27/25	3 Months Ago 1/27/24 to 1/26/25	1 Year Ago 4/27/23 to 4/26/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	18 Buy rating(s)	17 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$71.94	$70.41	$68.71	$89.44
Forecasted Upside	10.17% Upside	4.17% Upside	25.59% Upside	33.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.17% Upside	2,806.58% Upside	21.41% Upside
News Sentiment Rating	Positive News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/15/2025	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight
4/15/2025	Robert W. Baird 2 of 5 stars	Michael Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$51.00 ➝ $71.00	+2.68%
4/11/2025	Truist Financial 2 of 5 stars	David Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$76.00 ➝ $82.00	+19.09%
4/9/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$70.00 ➝ $76.00	+12.36%
3/21/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$72.00 ➝ $74.00	+7.70%
2/18/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target		$77.00	+16.93%
2/18/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$80.00 ➝ $81.00	+23.71%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$68.00 ➝ $73.00	+11.76%
2/13/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$71.00 ➝ $73.00	+15.45%
2/13/2025	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$55.00 ➝ $75.00	+18.61%
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
2/12/2025	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
2/12/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
2/11/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	67.00 ➝ 70.00
2/11/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$62.00 ➝ $59.00	+7.25%
1/30/2025	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
1/27/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$60.00 ➝ $65.00	+15.59%
12/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$66.00 ➝ $66.00	+11.73%
11/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Rhyee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$73.00 ➝ $80.00	+33.11%
11/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$68.00 ➝ $58.00	+8.33%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $77.00	+41.73%
5/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $74.00	+36.08%
12/22/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$94.00	+19.56%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$93.00 ➝ $80.00	+11.41%
8/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $85.00	+14.34%
5/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $96.00	+35.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:34 PM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 24, 2025. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent ratings include an "overweight" from Morgan Stanley and a "strong buy" from Leerink Partners.
The stock price is currently around $65.86, which is significantly higher than its one-year low of $43.56, suggesting a positive trend in its market performance.
Analysts have set an average price target of approximately $71.83, which indicates potential upside for investors based on current trading levels.
CVS Health Co. has a solid market capitalization of over $83 billion, reflecting its stability and presence in the healthcare sector.
The company has a relatively low debt-to-equity ratio of 0.80, which suggests that it is not overly reliant on debt to finance its operations, making it a potentially safer investment.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

Despite recent upgrades, there are still four analysts who have rated the stock as a hold, indicating some uncertainty about its future performance.
The stock has a beta of 0.57, which suggests lower volatility compared to the market, but may also indicate limited growth potential in a bullish market.
Insider trading activity shows that a senior vice president sold a significant number of shares recently, which could raise concerns about the company's short-term outlook.
The current ratio of 0.81 indicates that the company may have some challenges in meeting its short-term liabilities, which could be a red flag for investors.
While the stock has performed well recently, it is still below its one-year high of $71.45, suggesting that it may face resistance in reaching new highs.

CVS Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $71.94, with a high forecast of $82.00 and a low forecast of $58.00.
: 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 3 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CVS shares.
: According to analysts, CVS Health's stock has a predicted upside of 10.17% based on their 12-month stock forecasts.
: Over the previous 90 days, CVS Health's stock had 4 upgrades by analysts.
: CVS Health has been rated by research analysts at Argus, Barclays, Cantor Fitzgerald, Edward Jones, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Truist Financial, UBS Group, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like CVS Health more than other "medical" companies. The consensus rating score for CVS Health is 2.91 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:CVS) was last updated on 4/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target